Oculis Holding AG (OCS)
Automate Your Wheel Strategy on OCS
With Tiblio's Option Bot, you can configure your own wheel strategy including OCS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OCS
- Rev/Share 0.0
- Book/Share 2.7366
- PB 5.1147
- Debt/Equity 0.0072
- CurrentRatio 4.5477
- ROIC -0.5225
- MktCap 732553876.3566
- FreeCF/Share -1.1175
- PFCF -12.5371
- PE -6.8126
- Debt/Assets 0.0057
- DivYield 0
- ROE -0.906
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OCS | Needham | -- | Buy | -- | $36 | Aug. 27, 2025 |
News
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025.
Read More
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025.
Read More
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Oculis Holding AG (OCS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.56 per share a year ago.
Read More
Oculis Publishes Results of 2025 Annual General Meeting
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
Read More
Oculis Publishes Results of 2025 Annual General Meeting
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
Read More
Oculis to Participate in Upcoming June Investor Conferences
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:
Read More
Oculis to Participate in Upcoming June Investor Conferences
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:
Read More
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Oculis Holding AG (OCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Oculis to Present at Upcoming May Investor Conferences
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:
Read More
Oculis to Present at Upcoming May Investor Conferences
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:
Read More
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC).
Read More
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC).
Read More
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).
Read More
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).
Read More
About Oculis Holding AG (OCS)
- IPO Date 2021-05-18
- Website https://oculis.com
- Industry Biotechnology
- CEO Riad Sherif
- Employees 49